OTCMKTS:ARPO - Aerpio Pharmaceuticals Stock Price, Forecast & News Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Aerpio Pharmaceuticals Inc Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add $0.65 0.00 (0.00 %) (As of 02/17/2020 02:13 AM ET) Add Compare Today's Range$0.65Now: $0.65▼$0.6950-Day Range$0.58MA: $0.64▼$0.7152-Week Range$0.45Now: $0.65▼$4.25Volume89,243 shsAverage Volume371,097 shsMarket Capitalization$26.52 millionP/E RatioN/ADividend YieldN/ABetaN/A ProfileAnalyst RatingsAdvanced ChartEarningsInsider TradesInstitutional OwnershipHeadlinesSocial Media Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email Aerpio Pharmaceuticals, Inc, a biopharmaceutical company, develops and commercializes proprietary therapeutics for treating ocular diseases. The company's lead product candidate is AKB-9778, a small molecule activator of the tie-2 pathway, which completed Phase 2a clinical trials for the treatment of diabetic macular edema. It also develops ARP-1536, a humanized monoclonal antibody that is in late stage preclinical development for the treatment of wet age-related macular degeneration; and AKB-4924, a selective stabilizer of hypoxia-inducible factor-1 alpha, which has completed a Phase 1a clinical trial for the treatment of inflammatory bowel disease. Read More… Industry, Sector and Symbol Stock Exchange OTCMKTS Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolOTCMKTS:ARPO Previous Symbol CUSIPN/A CIKN/A Webhttp://www.aerpio.com/ Phone513-985-1920Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/APrice-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book ValueN/A Price / BookN/AProfitability EPS (Most Recent Fiscal Year)N/A Net IncomeN/A Net MarginsN/A Return on EquityN/A Return on AssetsN/AMiscellaneous EmployeesN/A Outstanding Shares40,588,000Market Cap$26.52 million Next Earnings DateN/A OptionableNot Optionable Receive ARPO News and Ratings via Email Sign-up to receive the latest news and ratings for ARPO and its competitors with MarketBeat's FREE daily newsletter. OTC:ARPO Rates by TradingView Aerpio Pharmaceuticals (OTCMKTS:ARPO) Frequently Asked Questions What is Aerpio Pharmaceuticals' stock symbol? Aerpio Pharmaceuticals trades on the OTCMKTS under the ticker symbol "ARPO." How were Aerpio Pharmaceuticals' earnings last quarter? Aerpio Pharmaceuticals Inc (OTCMKTS:ARPO) posted its earnings results on Thursday, November, 7th. The company reported ($0.11) earnings per share for the quarter, topping the Thomson Reuters' consensus estimate of ($0.13) by $0.02. View Aerpio Pharmaceuticals' Earnings History. What price target have analysts set for ARPO? 4 brokers have issued 1-year price targets for Aerpio Pharmaceuticals' shares. Their forecasts range from $1.00 to $8.00. On average, they expect Aerpio Pharmaceuticals' stock price to reach $4.50 in the next year. This suggests a possible upside of 588.6% from the stock's current price. View Analyst Price Targets for Aerpio Pharmaceuticals. What is the consensus analysts' recommendation for Aerpio Pharmaceuticals? 4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Aerpio Pharmaceuticals in the last year. There are currently 3 hold ratings and 1 buy rating for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Aerpio Pharmaceuticals. What are Wall Street analysts saying about Aerpio Pharmaceuticals stock? Here are some recent quotes from research analysts about Aerpio Pharmaceuticals stock: 1. According to Zacks Investment Research, "Aerpio Pharmaceuticals Inc. is a biopharmaceutical company. It focuses on the development of novel therapeutics for vascular disorders with a concentration on diseases of the eye. The Company' product candidates include AKB?9778, ARP1536 and AKB-4924 which are in clinical stage. Aerpio Pharmaceuticals Inc. is based in Cincinnati, United States. " (2/13/2020) 2. HC Wainwright analysts commented, "Our price target is derived from an estimated market value of the firm at $43M, which includes a discounted cash flow- based asset value for AKB-9778 in glaucoma and AKB-4924 (GB004) in inflammatory bowel disease (IBS), using a 15% discount rate and 2% terminal growth rate, and probabilities of success at 20% and 10%,." (8/9/2019) Has Aerpio Pharmaceuticals been receiving favorable news coverage? Media stories about ARPO stock have been trending somewhat positive on Monday, InfoTrie reports. The research firm identifies negative and positive news coverage by analyzing more than six thousand blog and news sources in real-time. The firm ranks coverage of public companies on a scale of negative five to five, with scores nearest to five being the most favorable. Aerpio Pharmaceuticals earned a news impact score of 2.0 on InfoTrie's scale. They also assigned news stories about the company a news buzz of 0.0 out of 10, meaning that recent news coverage is extremely unlikely to have an impact on the company's share price in the near term. View News Stories for Aerpio Pharmaceuticals. Who are some of Aerpio Pharmaceuticals' key competitors? Some companies that are related to Aerpio Pharmaceuticals include OASMIA PHARMACE/ADR (OASM), Axovant Gene Therapies (AXGT), AVEO Pharmaceuticals (AVEO), ASLAN PHARMACEU/ADR (ASLN), American Brivision (Holding) (ABVC), Alpine Immune Sciences (ALPN), Aridis Pharmaceuticals (ARDS), Annovis Bio (ANVS), Fibrocell Science (FCSC), AzurRx BioPharma (AZRX), Aptevo Therapeutics (APVO), Aileron Therapeutics (ALRN), OHR Pharmaceutical (OHRP), Aytu Bioscience (AYTU) and Novelion Therapeutics (NVLN). What other stocks do shareholders of Aerpio Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some companies that other Aerpio Pharmaceuticals investors own include Bausch Health Companies (BHC), Corbus Pharmaceuticals (CRBP), MannKind (MNKD), Actinium Pharmaceuticals (ATNM), AVEO Pharmaceuticals (AVEO), BIOLINERX LTD/S (BLRX), Eyegate Pharmaceuticals (EYEG), Progenics Pharmaceuticals (PGNX), Sorrento Therapeutics (SRNE) and Anavex Life Sciences (AVXL). Who are Aerpio Pharmaceuticals' key executives? Aerpio Pharmaceuticals' management team includes the folowing people: Dr. Joseph H. Gardner, Founder, Pres & Director (Age 62)Mr. Kevin G. Peters M.D., Ph.D., Chief Scientific Officer & Sr. VP (Age 61)Dr. Stephen Pakola M.D., Chief Medical Officer (Age 49)Dr. Stephen J. Hoffman, CEO & Director (Age 64)Mr. Michael W. Rogers, Chief Financial Officer (Age 58) Who are Aerpio Pharmaceuticals' major shareholders? Aerpio Pharmaceuticals' stock is owned by a number of of retail and institutional investors. Top institutional shareholders include Goldman Sachs Group Inc. (2.02%) and Renaissance Technologies LLC (1.00%). Company insiders that own Aerpio Pharmaceuticals stock include Bioventures Ltd Novartis, Joseph H Gardner, Muneer A Satter and Stephen J Hoffman. View Institutional Ownership Trends for Aerpio Pharmaceuticals. Which institutional investors are selling Aerpio Pharmaceuticals stock? ARPO stock was sold by a variety of institutional investors in the last quarter, including Goldman Sachs Group Inc.. View Insider Buying and Selling for Aerpio Pharmaceuticals. Which institutional investors are buying Aerpio Pharmaceuticals stock? ARPO stock was acquired by a variety of institutional investors in the last quarter, including Renaissance Technologies LLC. Company insiders that have bought Aerpio Pharmaceuticals stock in the last two years include Joseph H Gardner, Muneer A Satter and Stephen J Hoffman. View Insider Buying and Selling for Aerpio Pharmaceuticals. How do I buy shares of Aerpio Pharmaceuticals? Shares of ARPO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab. What is Aerpio Pharmaceuticals' stock price today? One share of ARPO stock can currently be purchased for approximately $0.65. How big of a company is Aerpio Pharmaceuticals? Aerpio Pharmaceuticals has a market capitalization of $26.52 million. View Additional Information About Aerpio Pharmaceuticals. What is Aerpio Pharmaceuticals' official website? The official website for Aerpio Pharmaceuticals is http://www.aerpio.com/. How can I contact Aerpio Pharmaceuticals? Aerpio Pharmaceuticals' mailing address is 9987 CARVER ROAD, CINCINNATI OH, 45242. The company can be reached via phone at 513-985-1920 or via email at [email protected] MarketBeat Community Rating for Aerpio Pharmaceuticals (OTCMKTS ARPO)Community Ranking: 2.4 out of 5 ( )Outperform Votes: 89 (Vote Outperform)Underperform Votes: 94 (Vote Underperform)Total Votes: 183MarketBeat's community ratings are surveys of what our community members think about Aerpio Pharmaceuticals and other stocks. Vote "Outperform" if you believe ARPO will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ARPO will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 2/17/2020 by MarketBeat.com StaffFeatured Article: What is the S&P/ASX 200 Index?
